FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415577981> ?p ?o ?g. }

• W2415577981 endingPage "64" @default.
• W2415577981 startingPage "1059" @default.
• W2415577981 abstract "This study is the first randomized prospective clinical trial of interferon in hepatitis to be conducted according to the guidelines of Good Clinical Practice (GCP) in China. The object of this study is to compare the long-term efficacy of a dose of 3MU of recombinant IFN alpha 2a (rIFN-alpha 2a) three times a week (t.i.w.) for 6 months with a starting dose of 6MU for 3 months and subsequent reduction to 3 MU t.i.w for a further 3 months.Sixty-eight serological and histologically proven chronic hepatitis C patients with elevated serum ALT were randomized into two groups. A total of 63 patients were studied with full course of treatment. Five patients were withdrawn from the trial, 2 due to personal reasons and 3 due to adverse drug reactions during treatment. Thirty patients received 6MU IFN-alpha 2a t.i.w. for 3 months followed by 3MU t.i.w. for another 3 months (group A). Thirty-three patients received 3MU IFN-alpha 2a t.i.w. for 6 months (group B).The sex, age, baseline serum bilirubin, ALT and AST levels were matched in both groups. At the end of 6 months the complete and partial response rates in group A were 60.0% and 16.7%, respectively, and the clearance of serum HCV-RNA was 53.3%. In group B, the complete and partial response rates were 72.7% and 3.0%, respectively, and the clearance of HCV-RNA was 61.3%. These patients were followed up for 6, 12, and 18 months after stopping treatment. In group A, the rates of complete normalization of ALT and clearance of serum HCV-RNA at 24 months were 50.0% and 60.0%, respectively. In group B, the rates of normalization of ALT and clearance of HCV-RNA at 24 months were 54.4% and 41.9%, respectively. The efficacy between the two groups showed no statistically significant difference; the response rates of treatment were similar to the patients with HCV genotype 1b and 2a. Six patients (10.8% of the study population) developed neutralization antibodies to IFN-alpha 2a during treatment, 4 of them responded to the treatment. Adverse drug reactions (ADR) were common, but most of them were tolerable and the incidence of ADR was similar in both groups.IFN-alpha 2a is effective in the treatment of Chinese patients with chronic hepatitis C. The sustained response rates and ADR among two dose schedule groups are similar." @default.
• W2415577981 created "2016-06-24" @default.
• W2415577981 creator A5003969752 @default.
• W2415577981 creator A5023976386 @default.
• W2415577981 creator A5038606305 @default.
• W2415577981 creator A5048736665 @default.
• W2415577981 creator A5064621040 @default.
• W2415577981 creator A5065062996 @default.
• W2415577981 creator A5075150104 @default.
• W2415577981 date "1999-06-17" @default.
• W2415577981 modified "2023-09-27" @default.
• W2415577981 title "Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients." @default.
• W2415577981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10370667" @default.
• W2415577981 hasPublicationYear "1999" @default.
• W2415577981 type Work @default.
• W2415577981 sameAs 2415577981 @default.
• W2415577981 citedByCount "2" @default.
• W2415577981 crossrefType "journal-article" @default.
• W2415577981 hasAuthorship W2415577981A5003969752 @default.
• W2415577981 hasAuthorship W2415577981A5023976386 @default.
• W2415577981 hasAuthorship W2415577981A5038606305 @default.
• W2415577981 hasAuthorship W2415577981A5048736665 @default.
• W2415577981 hasAuthorship W2415577981A5064621040 @default.
• W2415577981 hasAuthorship W2415577981A5065062996 @default.
• W2415577981 hasAuthorship W2415577981A5075150104 @default.
• W2415577981 hasConcept C126322002 @default.
• W2415577981 hasConcept C141071460 @default.
• W2415577981 hasConcept C159654299 @default.
• W2415577981 hasConcept C168563851 @default.
• W2415577981 hasConcept C188816634 @default.
• W2415577981 hasConcept C197934379 @default.
• W2415577981 hasConcept C203014093 @default.
• W2415577981 hasConcept C2522874641 @default.
• W2415577981 hasConcept C2776029263 @default.
• W2415577981 hasConcept C2776178377 @default.
• W2415577981 hasConcept C2909179924 @default.
• W2415577981 hasConcept C3020491458 @default.
• W2415577981 hasConcept C45189115 @default.
• W2415577981 hasConcept C535046627 @default.
• W2415577981 hasConcept C71924100 @default.
• W2415577981 hasConcept C90924648 @default.
• W2415577981 hasConceptScore W2415577981C126322002 @default.
• W2415577981 hasConceptScore W2415577981C141071460 @default.
• W2415577981 hasConceptScore W2415577981C159654299 @default.
• W2415577981 hasConceptScore W2415577981C168563851 @default.
• W2415577981 hasConceptScore W2415577981C188816634 @default.
• W2415577981 hasConceptScore W2415577981C197934379 @default.
• W2415577981 hasConceptScore W2415577981C203014093 @default.
• W2415577981 hasConceptScore W2415577981C2522874641 @default.
• W2415577981 hasConceptScore W2415577981C2776029263 @default.
• W2415577981 hasConceptScore W2415577981C2776178377 @default.
• W2415577981 hasConceptScore W2415577981C2909179924 @default.
• W2415577981 hasConceptScore W2415577981C3020491458 @default.
• W2415577981 hasConceptScore W2415577981C45189115 @default.
• W2415577981 hasConceptScore W2415577981C535046627 @default.
• W2415577981 hasConceptScore W2415577981C71924100 @default.
• W2415577981 hasConceptScore W2415577981C90924648 @default.
• W2415577981 hasIssue "26" @default.
• W2415577981 hasLocation W24155779811 @default.
• W2415577981 hasOpenAccess W2415577981 @default.
• W2415577981 hasPrimaryLocation W24155779811 @default.
• W2415577981 hasRelatedWork W2042319108 @default.
• W2415577981 hasRelatedWork W2123329760 @default.
• W2415577981 hasRelatedWork W2152805462 @default.
• W2415577981 hasRelatedWork W2153580290 @default.
• W2415577981 hasRelatedWork W2372542253 @default.
• W2415577981 hasRelatedWork W2374143509 @default.
• W2415577981 hasRelatedWork W2374920454 @default.
• W2415577981 hasRelatedWork W2415936779 @default.
• W2415577981 hasRelatedWork W2468074350 @default.
• W2415577981 hasRelatedWork W2979054247 @default.
• W2415577981 hasVolume "46" @default.
• W2415577981 isParatext "false" @default.
• W2415577981 isRetracted "false" @default.
• W2415577981 magId "2415577981" @default.
• W2415577981 workType "article" @default.